COVAXIN® (BBV152) Booster Shown to Neutralize Both Omicron and Delta Variants of SARS-CoV-2

Booster dose of vaccine, COVAXIN® (BBV152), generated robust neutralizing antibody  responses against both Omicron (B.1.529) and Delta (B.1.617.2) using a live virus  neutralization assay 

100% of test serum samples showed neutralization of the Delta variant and more than 90%  of serum samples showed neutralization of the Omicron variant 

These data add to the body of evidence that the broad-spectrum mechanism of action of a  whole virus inactivated COVID-19 vaccine, like COVAXIN® (BBV152), is a viable option in this  continuously evolving pandemic 


Hyderabad, India, January 12, 2022 - Bharat Biotech, a global leader in vaccine innovation and  developer of vaccines for infectious diseases, today announced results from a study conducted at  Emory University demonstrating that sera from subjects who received a booster dose of COVAXIN® (BBV152) six months after getting a primary two-dose series of COVAXIN® (BBV152), neutralized the SARS-CoV-2 Omicron and Delta variants. Earlier studies demonstrated the  neutralizing potential of COVAXIN® (BBV152) against SARS-CoV-2 Variants of Concern Alpha, Beta,  Delta, Zeta and Kappa. 

The study will be published on the pre-print server, medRXiv, shortly. 

Sera samples from individuals who received a booster of COVAXIN® (BBV152) were observed to  be effective in neutralizing Omicron and Delta variants on a live virus neutralization assay. The  neutralization activity of COVAXIN®-boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant. More than 90% of all individuals boosted with COVAXIN® (BBV152) showed neutralizing antibodies. All participants received an initial two dose schedule of COVAXIN® (BBV152) at Day 0 and Day 28. 

“As the dominant COVID-19 variant throughout the world, Omicron poses a serious public health  concern,” said Mehul Suthar, Ph.D., Assistant Professor, Emory Vaccine Center and who led the  laboratory analysis. “Data from this preliminary analysis show individuals receiving a booster dose  of COVAXIN® have a significant immune response to both the Omicron and Delta variants. These  findings suggest that a booster dose has the potential to reduce disease severity and hospitalizations.” 

Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said, “We are in a continuous  state of innovation and product development for COVAXIN®. The positive neutralization responses  against the Omicron and Delta variants, validates our hypothesis of a multi-epitope vaccine  generating both humoral and cell mediated immune responses. Our goals of developing a global  vaccine against COVID-19 have been achieved with the use of COVAXIN® as a universal vaccine for  adults and children.”

“The global impact of Omicron shows us that the fight against COVID-19 continues, and we’re  encouraged that these data demonstrate the value of COVAXIN® as a primary and booster  vaccine,” said Dr. Shankar Musunuri, Chairman, CEO and Co-Founder, Ocugen, Inc. “These results  show how a broad-spectrum vaccine has the potential ability to address ever-shifting public health  challenges such as new variants and mutations.” 

COVAXIN® is formulated uniquely such that the same dosage can be administered to adults and  children alike. COVAXIN® is a ready-to-use, liquid vaccine, stored at 2 - 8°C, with 12 months shelf  life and multi-dose vial policy. The same doses of vaccine can also be used for two-dose primary  immunization in adults and children and for booster dose vaccinations, making it truly a universal vaccine. 


About the study  

In order to evaluate the effectiveness of COVAXIN® (BBV152) against the Omicron variant, Ocugen  contracted with the Emory Vaccine Center (Atlanta, GA) to test human immune sera obtained  from participants (n=13) in an ongoing Phase 2 clinical trial ( NCT04471519). Sera  was collected 28-days post booster – six months following the primary two-dose series. Each sera  was tested in a neutralization assay. Following three doses, the FRNT50 geometric mean titers (GMTs) of neutralizing antibodies against the Omicron variant measured in the samples was 75,  compared to 480 against the Delta variant and 706 against the vaccine strain, D614G.  

This study was sponsored by Ocugen, Inc. and Ocugen’s partner, Bharat Biotech, provided the sera  of the subjects from the Phase 2 study. 

About COVAXIN® (BBV152)  

Covaxin was developed by Bharat Biotech in collaboration with the Indian Council of Medical  Research (ICMR) - National Institute of Virology (NIV). COVAXIN® (BBV152) is a highly purified and  inactivated vaccine that is manufactured using a vero cell manufacturing platform. 

With more than 200 million doses having been administered to adults and children outside the  U.S., COVAXIN® (BBV152) is currently authorized under emergency use in more than 20 countries,  and emergency use authorization is in process in more than 60 other countries. The World Health  Organization (WHO) recently added COVAXIN® (BBV152) to its list of vaccines authorized for  emergency use. And, as many as 110 countries have agreed to mutual recognition of COVID-19  vaccination certificates with India that includes vaccination using COVAXIN® (BBV152).  


About Bharat Biotech 

Bharat Biotech has established an excellent track record of innovation with more than 145 global  patents, a wide product portfolio of more than 16 vaccines, 4 bio-therapeutics, registrations in  more than 123 countries, and the World Health Organization (WHO) Pre-qualifications. Located  in Genome Valley in Hyderabad, India, a hub for the global biotech industry, Bharat Biotech has  built a world-class vaccine & bio-therapeutics, research & product development, Bio-Safety Level  3 manufacturing, and vaccine supply and distribution.  

Having delivered more than 4 billion doses of vaccines worldwide, Bharat Biotech continues to  lead innovation and has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis,  Rabies, Chikungunya, Zika, and the world’s first tetanus-toxoid conjugated vaccine for Typhoid.  Bharat’s commitment to global social innovation programs and public-private partnerships  resulted in introducing path-breaking WHO pre-qualified vaccines BIOPOLIO®, ROTAVAC®, and  Typbar TCV® combatting polio, rotavirus, typhoid infections, respectively. The acquisition of the  rabies vaccine facility, Chiron Behring, from GlaxoSmithKline (GSK) has positioned Bharat Biotech  as the world's largest rabies vaccine manufacturer. To learn more about Bharat Biotech, visit

About Ocugen, Inc.  

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and  commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives  from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat  multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate  aims to offer better therapy to patients with underserved diseases such as wet age-related  macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing  Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets. For  more information, please visit

Leave a Reply